Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
22 shown of 2,647 total abstracts
  1. Abstract LBA4000LBA2026-09-01 · 20:00 CT · S406
    FLAURA-767: Tagrisso (osimertinib) 2L in NSCLC
    J. Cortes, H. Borghaei, P. Schmid, et al. · Cleveland Clinic
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract LBA4001LBA2026-09-04 · 19:15 CT · Arie Crown Theater
    PACIFIC-426: Imfinzi (durvalumab) maintenance in SCLC
    H. Borghaei, N. Rizvi, E. Winer · Dana-Farber Cancer Institute
    Plenary SessionLung Cancer—Small Cell📄🖼️
  3. Abstract LBA4002LBA2026-09-04 · 13:45 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    F. Andre, G. Curigliano, H. Borghaei, et al. · University of Chicago
    Plenary SessionLung Cancer—Small Cell📄🖼️
  4. Abstract LBA4003LBA2026-09-04 · 18:45 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-253 study)
    S. Antonia, J. Cortes · Mayo Clinic
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract LBA4004LBA2026-09-02 · 16:00 CT · S406
    FLAURA-762: Tagrisso (osimertinib) 2L in NSCLC
    J. Brahmer, S. Tolaney · Mayo Clinic
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract LBA4005LBA2026-09-03 · 16:45 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-32 study)
    G. Curigliano, P. Schmid, N. Rizvi, et al. · Institut Gustave Roussy
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract LBA4006LBA2026-09-05 · 20:45 CT · Hall B1
    CheckMate-748: Opdivo (nivolumab) adjuvant in NSCLC
    N. Rizvi, A. Spira, M.C. Garassino, et al. · Chinese University of Hong Kong
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract LBA4007LBA2026-09-03 · 20:00 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-141
    S. Modi, M. Krop, M. Reck, et al. · Institut Gustave Roussy
    Plenary SessionLung Cancer—Small Cell📄🖼️
  9. Abstract LBA4008LBA2026-09-04 · 21:15 CT · Arie Crown Theater
    FLAURA-900: Tagrisso (osimertinib) 1L in NSCLC
    S. Tolaney, E. Winer, S. Antonia, et al. · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract LBA4009LBA2026-09-04 · 20:00 CT · Hall B1
    FLAURA-833: Tagrisso (osimertinib) neoadjuvant in NSCLC
    S. Modi, M. Reck, C. Robert · Royal Marsden Hospital
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract LBA4010LBA2026-09-03 · 14:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with SCLC
    R. Herbst, H. Rugo, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionLung Cancer—Small Cell📄🖼️
  12. Abstract LBA4011LBA2026-09-04 · 16:30 CT · Arie Crown Theater
    KEYNOTE-697: Keytruda (pembrolizumab) 3L+ in SCLC
    P. Schmid, S. Antonia, S. Modi, et al. · Cleveland Clinic
    Plenary SessionLung Cancer—Small Cell📄🖼️
  13. Abstract LBA4012LBA2026-09-02 · 15:30 CT · S100A
    IMpower-749: Tecentriq (atezolizumab) 1L in NSCLC
    R. Herbst, F. Andre, M. Reck, et al. · Peter MacCallum Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract LBA4013LBA2026-09-03 · 15:45 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-260
    S. Antonia, P. Schmid, R. Herbst, et al. · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract LBA4014LBA2026-09-05 · 14:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-544
    C. Robert, J. Brahmer, S. Tolaney, et al. · Chinese University of Hong Kong
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract LBA4015LBA2026-09-02 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-670
    F. Andre, J. Brahmer, P. Schmid, et al. · Royal Marsden Hospital
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract LBA4016LBA2026-09-01 · 14:00 CT · E450
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-19
    J. Cortes, H. Rugo, M. Krop, et al. · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract LBA4017LBA2026-09-03 · 16:00 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-310 study)
    M. Reck, J. Cortes, J. Brahmer · Cleveland Clinic
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract LBA4018LBA2026-09-01 · 21:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-419
    R. Herbst, H. Rugo, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract LBA4019LBA2026-09-01 · 18:30 CT · E450
    Quality of life outcomes with Tecentriq in patients with NSCLC
    A. Spira, H. Borghaei · National Cancer Center Japan
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract LBA4020LBA2026-09-05 · 15:00 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-877 study)
    F. Andre, E. Winer, S. Tolaney · Peter MacCallum Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract LBA4021LBA2026-09-04 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-915 study)
    E. Winer, F. Andre, M. Reck, et al. · Dana-Farber Cancer Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.